Search results for: 'Installation Material'

This research service analyzes and provides forecasts of the US hematology diagnostics market from 2012 to 2017. The market is broadly classified into 2 major segments: analyzers and reagents. The US hematology market was sized using a bottom-up revenue model developed from the actual installed base of hematology analyzers in US laboratories, the d...

The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

This study provides market data for the US Urinalysis Market. Market segments include sediment and dipstick. Sediment and dipstick are further segmented by instruments and reagents. In this deliverable, market revenues, installed base units, and market share are included. Further analysis will be provided in a separate deliverable to accompany this...

The Affordable Care Act has created an upswing in the number of patients entering the US healthcare system, boosting the volume of routine and specialized testing performed in laboratories. This market insight analyzes the instrumentation and reagent segment activity within the US hemostasis market. Key trends and a comparative analysis between the...

This research service pertains to the US market for nuclear medicine and positron emission tomography (PET) imaging systems. Providing thorough market sizing and forecast of market revenue, unit shipments, procedure volumes, average pricing, and installed base, the study analyzes market trends, drivers and restraints, along with the reimbursement a...

The immunoassay and clinical chemistry market is the highest share contributor for the total in vitro diagnostics (IVD) market. Globally valued at $28.7 billion in 2019, this market segment contributes 37.6% of the total IVD market of $76.3 billion. Within the high-medium to low analyzer segment, there are over 40 companies globally. Of these, 14 c...

Continuous manufacturing (CM) is a method for manufacturing end-to-end pharmaceutical products on a single, uninterrupted production line. While batch manufacturing requires transporting, testing, and refeeding materials from one process to the next, continuous processes execute all testing, feeding, and processing inline at a single manufacturing ...